These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Regarding Waldinger and Schweitzer's "premature ejaculation and pharmaceutical company-based medicine: the dapoxetine case". Goldstein I J Sex Med; 2008 Apr; 5(4):965. PubMed ID: 18371046 [No Abstract] [Full Text] [Related]
5. Pharmacokinetic and pharmacodynamic features of dapoxetine, a novel drug for 'on-demand' treatment of premature ejaculation. Andersson KE; Mulhall JP; Wyllie MG BJU Int; 2006 Feb; 97(2):311-5. PubMed ID: 16430636 [TBL] [Abstract][Full Text] [Related]
7. Medical therapy for premature ejaculation. Montorsi F; Salonia A Lancet; 2006 Sep; 368(9539):894-6. PubMed ID: 16962861 [No Abstract] [Full Text] [Related]
8. Editorial comment on: Dapoxetine for the treatment of premature ejaculation: results from a randomized, double-blind, placebo-controlled phase 3 trial in 22 countries. Jannini EA Eur Urol; 2009 Apr; 55(4):967-8. PubMed ID: 19195773 [No Abstract] [Full Text] [Related]
9. Treatment of premature ejaculation in the Asia-Pacific region: results from a phase III double-blind, parallel-group study of dapoxetine. McMahon C; Kim SW; Park NC; Chang CP; Rivas D; Tesfaye F; Rothman M; Aquilina J; J Sex Med; 2010 Jan; 7(1 Pt 1):256-68. PubMed ID: 19878447 [TBL] [Abstract][Full Text] [Related]
10. Efficacy and tolerability of dapoxetine in treatment of premature ejaculation: an integrated analysis of two double-blind, randomised controlled trials. Pryor JL; Althof SE; Steidle C; Rosen RC; Hellstrom WJ; Shabsigh R; Miloslavsky M; Kell S; Lancet; 2006 Sep; 368(9539):929-37. PubMed ID: 16962882 [TBL] [Abstract][Full Text] [Related]
11. Distress, disease, desire: perspectives on the medicalisation of premature ejaculation. Söderfeldt Y; Droppe A; Ohnhäuser T J Med Ethics; 2017 Dec; 43(12):865-866. PubMed ID: 28341756 [TBL] [Abstract][Full Text] [Related]
12. Treatment benefit of dapoxetine for premature ejaculation: results from a placebo-controlled phase III trial. Kaufman JM; Rosen RC; Mudumbi RV; Tesfaye F; Hashmonay R; Rivas D BJU Int; 2009 Mar; 103(5):651-8. PubMed ID: 19021601 [TBL] [Abstract][Full Text] [Related]
13. W is for Wilbert's wee willy (which tends to go off prematurely). Cassels A CMAJ; 2007 Sep; 177(7):816. PubMed ID: 17893357 [No Abstract] [Full Text] [Related]
14. Baseline characteristics and treatment outcomes for men with acquired or lifelong premature ejaculation with mild or no erectile dysfunction: integrated analyses of two phase 3 dapoxetine trials. Porst H; McMahon CG; Althof SE; Sharlip I; Bull S; Aquilina JW; Tesfaye F; Rivas DA J Sex Med; 2010 Jun; 7(6):2231-2242. PubMed ID: 20412423 [TBL] [Abstract][Full Text] [Related]
15. A benefit-risk assessment of dapoxetine in the treatment of premature ejaculation. Hutchinson K; Cruickshank K; Wylie K Drug Saf; 2012 May; 35(5):359-72. PubMed ID: 22452563 [TBL] [Abstract][Full Text] [Related]
19. Comparison of dapoxetine versus paroxetine in patients with premature ejaculation: a double-blind, placebo-controlled, fixed-dose, randomized study. Safarinejad MR Clin Neuropharmacol; 2006; 29(5):243-52. PubMed ID: 16960468 [TBL] [Abstract][Full Text] [Related]
20. Perceived control over ejaculation is central to treatment benefit in men with premature ejaculation: results from phase III trials with dapoxetine. Shabsigh R; Patrick DL; Rowland DL; Bull SA; Tesfaye F; Rothman M BJU Int; 2008 Sep; 102(7):824-8. PubMed ID: 18647300 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]